The programme of this “How to Diagnose and Treat: Acute Leukaemias” includes genomic analysis and cutting-edge technics in routine diagnosis, targeted therapies and standard of care treatments allogeneic haematopoietic stem cell transplantation (HSCT) transplantation and innovative immunotherapies, as well as diagnosis and management of rare acute leukaemia subtypes. Clonal hematopoiesis will be covered in detail. Novel trial designs instrumental for smarter drug development is discussed in a separate session.
This conference is accredited by the European Board for Accreditation in Hematology (EBAH) CME system. Participants will be eligible to claim CME credit points.
The meeting will be of interest to:
• Senior biologists and clinicians, including experts in the field (MD, PhD, MD-PhD)
• Junior scientists and clinicians (MD, PhD)
• PhD candidates and clinical residents still in-training
Learning Objectives:
Knowledge of Classification of ALL and AML
Insight in prognosis of ALL and AML
Application of MRD
Knowledge of established and novel treatment options in ALL and AML
Indications of alloSCT
Management of challenging subgroups of AML and ALL
Controversies on clinical trials and treatment options
Scientific Topics:
– Dilemmas in acute leukaemias
– Novel treatments
– Diagnosis and treatment of rare diseases and rare subsets
– MRD a proper surrogate endpoint in AML
– Optimizing outcomes in acute leukaemias using supportive strategies
– Immune targeting strategies in ALL
– Real-world AML therapy
– Blina-TKI is enough to cure Ph-positive ALL
– HSC transplantation
– Leukaemia treatment challenges
The programme will include:
- Plenary Sessions
- Interactive Case Presentations
- Roundtables
- Panel Discussions
- Debates
- Poster Walks
- Meet the Expert Sessions
- Voting technology
- Ample time for in-depth discussion
Register here
Direct email queries to: [email protected]
